A18 | Naïve CD4+ T cells form the bulk of the translation competent HIV-1 reservoir in vertically infected children and adolescents | Oral abstract session with live Q&A | Cellular and tissue reservoirs of HIV/SIV |
A18 | Naive infection predicts HIV reservoir size and diversity in individuals with a spectrum of immunological control | E-poster | Cellular and tissue reservoirs of HIV/SIV |
C41 | Navigating PrEP use and pregnancy: perspectives among adolescent girls and young women (AGYW) in Tshwane, South Africa | E-poster | PrEP and pregnant women |
B67 | Neuropsychiatric manifestations and sleep disturbances in children and adolescents randomised to dolutegravir-based ART vs standard-of-care in the ODYSSEY trial | On-demand oral abstract session | Mental health and neurocognition in paediatric and adolescent populations |
A6 | Neutralizing antibody induction associated with a germline immunoglobulin gene polymorphism in rhesus macaques after neutralization-resistant SIVsmE543-3 infection | E-poster | Humoral immunity (including broadly neutralizing antibodies) |
B45 | New generation of HYBRID CAR-T cells efficiently kill HIV infected cells and neutralize cell-free virus | On-demand oral abstract session | Immune-based therapy trials |
C32 | Next generation 3D-printed intravaginal rings for prevention of HIV and unplanned pregnancy | E-poster | Novel delivery systems (e.g., rings, implants, transdermal systems) |
B37 | NNRTI MK-8507 does not alter the pharmacokinetics of the combined oral contraceptive levonorgestrel/ethinyl estradiol | E-poster | Drug interactions |
B59 | No age-related difference in dolutegravir metabolic glucuronidation ratio in children between 3 months and 18 years old in the ODYSSEY trial | E-poster | Pharmacokinetics, pharmacodynamics, pharmacogenomics and therapeutic drug monitoring in paediatric and adolescent populations |
C41 | No association between prenatal PrEP exposure and adverse growth outcomes among Kenyan infants: a prospective study | E-poster | PrEP and pregnant women |